2012
DOI: 10.1016/j.jchromb.2012.03.040
|View full text |Cite
|
Sign up to set email alerts
|

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 12 publications
0
1
0
Order By: Relevance
“…Here, we report the signal enhancement achievable for 13 C 1 ‐pyruvate and 13 C u ‐glucose‐d7 using direct injection into a tumor‐supplying artery. Additionally, in vivo monitoring of drug metabolism was evaluated for the first time by administering a custom synthesized hyperpolarized 13 C‐labeled version of the vascular disrupting pro‐drug, combretastatin A‐1‐diphosphate (CA1‐P) .…”
Section: Introductionmentioning
confidence: 99%
“…Here, we report the signal enhancement achievable for 13 C 1 ‐pyruvate and 13 C u ‐glucose‐d7 using direct injection into a tumor‐supplying artery. Additionally, in vivo monitoring of drug metabolism was evaluated for the first time by administering a custom synthesized hyperpolarized 13 C‐labeled version of the vascular disrupting pro‐drug, combretastatin A‐1‐diphosphate (CA1‐P) .…”
Section: Introductionmentioning
confidence: 99%